Atrium Therapeutics, Inc. - Common Stock (RNA)

CUSIP: 05370A108

Q3 2024 13F Holders as of 30 Sep 2024

Type / Class
Equity / Common Stock
Shares outstanding
150,858,761
Total 13F shares
126,231,192
Share change
+11,772,792
Total reported value
$5,796,026,453
Put/Call ratio
72%
Price per share
$45.93
Number of holders
240
Value change
+$574,015,774
Number of buys
153
Number of sells
83

Quarterly Holders Quick Answers

What is CUSIP 05370A108?
CUSIP 05370A108 identifies RNA - Atrium Therapeutics, Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Atrium Therapeutics, Inc. - Common Stock (RNA) as of Q3 2024

As of 30 Sep 2024, Atrium Therapeutics, Inc. - Common Stock (RNA) was held by 240 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 126,231,192 shares. The largest 10 holders included FMR LLC, PRICE T ROWE ASSOCIATES INC /MD/, BlackRock, Inc., VANGUARD GROUP INC, RTW INVESTMENTS, LP, WELLINGTON MANAGEMENT GROUP LLP, Avoro Capital Advisors LLC, RA CAPITAL MANAGEMENT, L.P., JANUS HENDERSON GROUP PLC, and STATE STREET CORP. This page lists 241 institutional shareholders reporting positions in this security for the Q3 2024 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.